This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The total costs per patient tested were not given.
Using a prevalence of 15% and an annual number of endoscopies of 104 (+/-19), the total annual savings at CabellHuntington Hospital were estimated as $265.
Using a prevalence of 15% and an annual number of endoscopies of 768 (+/-102), the total annual savings at the Children's Hospital of Columbus were estimated as $1,985.
Synthesis of costs and benefits
Not applicable.
Authors' conclusions
"Reuse of a negative CLOtest (rapid urease test) is reliable and may reduce costs, especially in facilities with a high volume of endoscopic procedures."
CRD COMMENTARY -Selection of comparators
The comparator selected was appropriate given its use in practice.
Validity of estimate of measure of effectiveness
Sensitivity and specificity were appropriate measures of effectiveness. The study design was appropriate for the study question. A good feature of the design was the blinding of the technicians. However, it was unclear how the results of the histologic tests were synthesised to make the definitive diagnosis. Also, the implications of a reused kit missing a positive test were not explored in terms of health and quality of life.
Validity of estimate of measure of benefit
Not appropriate, given the lack of a summary measure of benefit.
Validity of estimate of costs
Although some prices were given, the price year was not. In addition, some of the prices were charges, for which the breakdown in terms of resource quantities was unknown. Thus, the generalisability to other settings is hampered. The resource quantities were also taken from an earlier period and may not be valid for the test accuracy results. Finally, in order to calculate the savings, a prevalence of 15% was assumed since the total costs were not presented. However, there was no sensitivity analysis to account for differing prices, test accuracy or prevalence, which might occur in other settings. In fact, the present reviewer calculated the prevalence in the study to be much higher. It can be shown that the higher the prevalence, the more likely it is that false negatives will occur, and therefore the impact of any difference in sensitivity will increase.
Other issues
The results were compared with those of other studies. The authors also discussed the issue of generalisability in terms of the prevalence of H. pylori, and the accuracy of testing, which depends on several factors including previous medication usage. They do not seem to have reported their results selectively. The conclusions were consistent with the study population.
